<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083065</url>
  </required_header>
  <id_info>
    <org_study_id>MECOVAC-1</org_study_id>
    <nct_id>NCT05083065</nct_id>
  </id_info>
  <brief_title>Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine</brief_title>
  <acronym>MECOVAC-1</acronym>
  <official_title>Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Covid-19 vaccines offered a good opportunity to counteract the spread of Sars-Cov-2 infection&#xD;
      among the general population, reducing significantly both morbidity and mortality.&#xD;
&#xD;
      Nevertheless, after the first and second doses of vaccination (regardless of the type of&#xD;
      vaccine used) several women required gynaecological visits claiming menstrual Irregularities&#xD;
      or abnormal uterine bleeding. Considering this anecdotal evidence, a questionnaire was&#xD;
      designed to investigate systematically whether menstrual Irregularities or abnormal uterine&#xD;
      bleeding occurred in a significant percentage of women undergoing first and second doses of&#xD;
      covid-19 vaccination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 21, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of the menstrual cycle</measure>
    <time_frame>30 days after the administration of the first and second doses of vaccine</time_frame>
    <description>In women of reproductive age, any frequency shorter than 25 days or longer than 36 days will be defined as abnormal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantity of the menstrual cycle</measure>
    <time_frame>30 days after the administration of the first and second doses of vaccine</time_frame>
    <description>In women of reproductive age, any quantity less than 30 ml or more than 80 ml will be defined as abnormal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of the menstrual cycle</measure>
    <time_frame>30 days after the administration of the first and second doses of vaccine</time_frame>
    <description>In women of reproductive age, any duration shorter than 3 days or longer than 7 days will be defined as abnormal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-menopausal bleeding</measure>
    <time_frame>30 days after the administration of the first and second doses of vaccine</time_frame>
    <description>Any bleeding occurred in post-menopausal women</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>Vaccine</condition>
  <condition>Menstrual Irregularity</condition>
  <condition>Menopausal Bleeding</condition>
  <arm_group>
    <arm_group_label>Women who underwent Covid-19 vaccination</arm_group_label>
    <description>This group includes women who underwent both the first or complete cycle of Covid-19 vaccination, regardless of the vaccine used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Covid-19 vaccine</intervention_name>
    <description>First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine&#xD;
First dose or complete cycle of Spikevax (Moderna) vaccine&#xD;
First dose or complete cycle of AstraZeneca/Vaxzevria vaccine&#xD;
Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose&#xD;
Janssen (Johnson &amp; Johnson) vaccine (single dose)</description>
    <arm_group_label>Women who underwent Covid-19 vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who underwent first dose or complete cycle of covid-19 vaccine, regardless of the&#xD;
        type of vaccine used.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who underwent first dose or complete cycle of covid-19 vaccine, regardless of&#xD;
             the type of vaccine used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women undergoing any kind of hormonal therapy, including combined oral contraceptives,&#xD;
             oral/vaginal progestins, intrauterine devices, GnRH-analogues, aromatase inhibitors,&#xD;
             hormonal replacement therapy in menopause;&#xD;
&#xD;
          -  Surgical menopause (hysterectomy and/or bilateral oophorectomy);&#xD;
&#xD;
          -  Breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Simone Laganà, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Simone Laganà, M.D., Ph.D.</last_name>
    <phone>+393296279579</phone>
    <email>antoniosimone.lagana@uninsubria.it</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Antonio Simone Laganà</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Covid-19 vaccine</keyword>
  <keyword>Menstrual Irregularity</keyword>
  <keyword>Menopausal Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

